United States · FDA National Drug Code directory

CARBIDOPA AND LEVODOPA

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference: 72865-363_28322507-e9f9-4b18-9f4b-ed28bb0a83bb
Product NDC: 72865-363
Form: TABLET
Composition / generic term: Carbidopa and Levodopa
Labeler: XLCare Pharmaceuticals, Inc.
Marketing category: ANDA
Marketing start / end (source format): 20260119
Source listing expiry: 20271231

Source-listed ingredients

CARBIDOPA — 25 mg/1
LEVODOPA — 250 mg/1

These values do not establish equivalence or a dose recommendation.

Packages

100 TABLET in 1 BOTTLE (72865-363-01) · 72865-363-01
1000 TABLET in 1 BOTTLE (72865-363-10) · 72865-363-10

Source and coverage

Open FDA National Drug Code directory →

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →